Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

Samankaltaisia teoksia

• Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
  Tekijä: Neelakantan, Pratap, et al.
  Julkaistu: (2013)
• Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
  Tekijä: Milojkovic, Dragana, et al.
  Julkaistu: (2012)
• Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
  Tekijä: Ibrahim, Amr R., et al.
  Julkaistu: (2010)
• The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
  Tekijä: Khorashad, Jamshid Sorouri, et al.
  Julkaistu: (2009)
• Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
  Tekijä: Ibrahim, Amr R., et al.
  Julkaistu: (2011)